JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2022, 71(4):135-139 | DOI: 10.5817/CSF2022-4-135

Selected polyphenolic compounds and their use as a supportive therapy in metabolic syndrome

Jan Soukop*, Rostislav Večeřa
Lékařská fakulta Univerzity Palackého, Ústav farmakologie, Olomouc

Metabolic syndrome is diagnosed mainly in people of economically developed parts of the world and it affects 20-25% of the adult population worldwide. Nowadays, it is also more frequently diagnosed in children and adolescents. In addition to standard treatment that often involves polypharmacotherapy, and thus increases risk of side effects caused by drugdrug interactions, it is appropriate to look for alternative tools to support the treatment of metabolic syndrome components. Natural polyphenolic compounds, usually present in the so-called functional foods, are suitable candidates for that matter, due to the bioactivity and beneficial effects on the human body. Quercetin, troxerutin, diosmin, hesperidin or silybin are among the currently studied and used natural polyphenolic compounds with a positive effect on aspects of the metabolic syndrome. In addition to their antioxidant and anti-inflammatory effects, these compounds have other positive properties that very often outweigh their side effects whilst their usage in the pharmacotherapy.

Keywords: diosmin; metabolic syndrome; quercetin; polyphenolic compounds; troxerutin; silymarin

Received: April 19, 2022; Accepted: June 9, 2022; Published: April 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soukop J, Večeřa R. Selected polyphenolic compounds and their use as a supportive therapy in metabolic syndrome. Čes. slov. farm. 2022;71(4):135-139. doi: 10.5817/CSF2022-4-135.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zhang S., Xu M., Zhang W., Liu C., Chen S. Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications. Int. J. Mol. Sci. 2021; 22, 6110. Go to original source... Go to PubMed...
    2. van den Brink W., van Bilsen J., Salic K., Hoevenaars F. P. M., Verschuren L., Kleemann R., Bouwman J., Ronnett G. V., van Ommen B., Wopereis S. Current and Future Nutritional Strategies to Modulate Inflammatory Dynamics in Metabolic Disorders. Front. Nutr. 2019; 6, 129. Go to original source... Go to PubMed...
    3. Lillich F. F., Imig J. D., Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front. Pharmacol. 2021; 11, 1996. Go to original source... Go to PubMed...
    4. Saif-Ali R., Kamaruddin N. A., Al-Habori M., Al-Dubai S. A., Wan Ngah W. Z. Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes. Diabetol Metab Syndr. 2020; 12, 1-7. Go to original source... Go to PubMed...
    5. Cardiovascular diseases (CVDs). https://www.who.int/newsroom/factsheets/detail/cardiovascular-diseases-(- cvds) (17. 1. 2022).
    6. Nasri H., Baradaran A., Shirzad H., Rafieian-Kopaei M. New Concepts in Nutraceuticals as Alternative for Pharmaceuticals. Int. J. Prev. Med. 2014; 5, 1487.
    7. Ohta T., Masutomi N., Tsutsui N., Sakairi T., Mitchell M., Milburn M. V., Ryals J. A., Beebe K. D., Guo L. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-Induced toxicology in fischer 344 male rats. Toxicol. Pathol. 2009; 37, 521-535. Go to original source... Go to PubMed...
    8. David A. V. A., Arulmoli R., Parasuraman S. Overviews of biological importance of quercetin: A bioactive flavonoid. Pharmacogn Rev. 2016; 10, 84-89. Go to original source... Go to PubMed...
    9. Quercetin | C15H10O7 - PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Quercetin (17. 1. 2022).
    10. Hollman P. C., de Vries J. H., van Leeuwen S. D., Mengelers M. J., Katan M. B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am. J. Clin. Nutr.1995; 62, 1276-1282. Go to original source... Go to PubMed...
    11. Boots A. W., Haenen G. R. M. M., Bast A. Health effects of quercetin: From antioxidant to nutraceutical. Eur. J. Pharmacol. 2008; 585, 325-337. Go to original source... Go to PubMed...
    12. Murota K., Hotta A., Ido H., Kawai Y., Moon J. H., Sekido K., Hayashi H., Inakuma T., Terao J. Antioxidant capacity of albumin-bound quercetin metabolites after onion consumption in humans. J. Med. Invest. 2007; 54, 370-374. Go to original source... Go to PubMed...
    13. Lakhanpal P., Rai D. K. Quercetin: A Versatile Flavonoid. IJMU 2007; 2, 20-35. Go to original source...
    14. Xiao X., Shi D., Liu L., Wang J., Xie X., Kang T., Deng W. Quercetin Suppresses Cyclooxygenase-2 Expression and Angiogenesis through Inactivation of P300 Signaling. PLoS One. 2011; 6, e22934. Go to original source... Go to PubMed...
    15. Askari G., Ghiasvand R., Feizi A., Ghanadian S. M., Karimian J. The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J Res Med Sci., 2012; 17, 637-641.
    16. Ahmad N. S., Farman M., Najmi M. H., Mian K. B., Hasan A. Pharmacological basis for use of Pistacia integerrima leaves in hyperuricemia and gout. J. Ethnopharmacol. Elsevier 2008; 117, 478-482. Go to original source... Go to PubMed...
    17. Ahmadi Z., Mohammadinejad R., Roomiani S., Afshar E. G., Ashrafizadeh M. Biological and Therapeutic Effects of Troxerutin: Molecular Signaling Pathways Come into View. J. Pharmacopunct. 2021; 24, 1-13. Go to original source... Go to PubMed...
    18. Badalzadeh R., Layeghzadeh N., Alihemmati A., Mohammadi M. Beneficial effect of troxerutin on diabetes- induced vascular damages in rat aorta: histopathological alterations and antioxidation mechanism. Int. J. Endocrinol. Metab. 2015; 13. Go to original source... Go to PubMed...
    19. Sampath S., Karundevi B. Effect of troxerutin on insulin signaling molecules in the gastrocnemius muscle of high fat and sucrose-induced type-2 diabetic adult male rat. Mol. Cell. Biochem. 2014; 395, 11-27. Go to original source... Go to PubMed...
    20. Geetha R., Yogalakshmi B., Sreeja S., Bhavani K., Anuradha C. V. Troxerutin suppresses lipid abnormalities in the heart of high-fat-high-fructose diet-fed mice. Mol. Cell. Biochem. 2014; 387, 123-134. Go to original source... Go to PubMed...
    21. Malinska H., Hüttl M., Oliyarnyk O., Markova I., Poruba M., Racova Z., Kazdova L., Vecera R. Beneficial effects of troxerutin on metabolic disorders in non-obese model of metabolic syndrome. PLoS One 2019; 14, e0220377. Go to original source... Go to PubMed...
    22. Karetova D., Suchopar J., Bultas J. Diosmin/hesperidin: A cooperating tandem, or is diosmin crucial and hesperidin an inactive ingredient only? Vnitř. Lék. 2020; 66, 97-103. Go to original source...
    23. Diosmin | C28H32O15 - PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Diosmin (17. 1. 2022).
    24. Diosmin | 520-27-4. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6443258.htm (17. 1. 2022).
    25. Silvestro L., Tarcomnicu I., Dulea C., Attili N. R. B. N., Ciuca V. Peru D., Savu S. R. Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquid-chromatography-mass spectrometry and ion mobility mass spectrometry. Anal. Bioanal. Chem. 2013; 405, 8295-8310. Go to original source... Go to PubMed...
    26. Gerges S. H., Wahdan S. A., Elsherbiny D. A., El-Demerdash E. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non- -alcoholic steatohepatitis in rats. oxicol. Appl. Pharmacol. 2020; 401, 115101. Go to original source... Go to PubMed...
    27. Diosmin Uses, Benefits & Dosage - Drugs.com Herbal Database. https://www.drugs.com/npp/diosmin.html (17. 1. 2022).
    28. Detralex | C56H66O30 - PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Detralex (17. 1. 2022).
    29. Hesperidin | C28H34O15 - PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Hesperidin (17. 1. 2022).
    30. Pereira-Caro G., Polyviou T., Ludwig I. A., Nastase A. M., Moreno-Rojas J. M., Garcia A. L., Malkova D., Crozier A. Bioavailability of orange juice (poly)phenols: the impact of short-term cessation of training by male endurance athletes. Am. J. Clin. Nutr. 2017; 106, 791- 800. Go to original source... Go to PubMed...
    31. Dhanya R., Jayamurthy P. In vitro evaluation of antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stress in skeletal muscle cell line. Cell Biochem. Funct. 2020; 38, 419-427. Go to original source... Go to PubMed...
    32. Mas-Capdevila A., Teichenne J., Domenech-Coca C., Caimari A., Del Bas J. M., Escoté X., Crescenti A. Effect of Hesperidin on Cardiovascular Disease Risk Factors: The Role of Intestinal Microbiota on Hesperidin Bioavailability. Nutrients 2020; 12, 1488. Go to original source... Go to PubMed...
    33. Jung U. J., Lee M. K., Park Y. B., Kang M. A., Choi M. S. Effect of citrus flavonoids on lipid metabolism and glucose- regulating enzyme mRNA levels in type-2 diabetic mice. Int. J. Biochem. Cell Biol. 2006; 38, 1134-1145. Go to original source... Go to PubMed...
    34. HESPERIDIN METHYLCHALCONE. https://drugs.ncats.io/drug/4T2GVA922X (17. 1. 2022).
    35. Koltai T., Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. J. Evid. Based Integr. Med. 2022; 27, 2515690X2110688. Go to original source... Go to PubMed...
    36. Skottova N., Krecman V. Silymarin as a potential hypocholesterolaemic drug. Physiol. Res. 1998; 47, 1-7.
    37. Camini F. C., da Silva T. F., da Silva Caetano C. C., Almeida L. T., Ferraz A. C., Alves Vitoreti V. M., de Mello Silva B., de Queiroz Silva S., de Magalhães J. C., de Brito Magalhães C. L. Antiviral activity of silymarin against Mayaro virus and protective effect in virus-induced oxidative stress. Antivir. Res. 2018; 158, 8-12. Go to original source... Go to PubMed...
    38. Vecera R., Zacharova A., Orolin J., Skottova N., Anzenbacher P. The effect of silymarin on expression of selected ABC transporters in the rat. Vet. Med. 2011; 56, 59-62. Go to original source...
    39. Calani L., Brighenti F., Bruni R., Del Rio D. Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine. 2012; 20, 40-46. Go to original source... Go to PubMed...
    40. Kidd P., Head K. A Review of the Bioavailability and Clinical Efficacy of Milk Thistle Phytosome: A Silybin-Phosphatidylcholine Complex (Siliphos®). Altern Med Rev. 2005; 10, 193-203.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.